Metabolomics as a tool for the early diagnosis and prognosis of diabetic kidney disease
PR Pereira, DF Carrageta, PF Oliveira… - Medicinal Research …, 2022 - Wiley Online Library
Diabetic kidney disease (DKD) is one of the most prevalent comorbidities of diabetes
mellitus and the leading cause of the end‐stage renal disease (ESRD). DKD results from …
mellitus and the leading cause of the end‐stage renal disease (ESRD). DKD results from …
[HTML][HTML] Mitochondria in diabetic kidney disease
AA Ahmad, SO Draves, M Rosca - Cells, 2021 - mdpi.com
Diabetic kidney disease (DKD) is the leading cause of end stage renal disease (ESRD) in
the USA. The pathogenesis of DKD is multifactorial and involves activation of multiple …
the USA. The pathogenesis of DKD is multifactorial and involves activation of multiple …
[HTML][HTML] The aggressive diabetic kidney disease in youth-onset type 2 diabetes: pathogenetic mechanisms and potential therapies
M Amatruda, G Gembillo, AE Giuffrida, D Santoro… - Medicina, 2021 - mdpi.com
Youth-onset Type 2 Diabetes Mellitus (T2DM) represents a major burden worldwide. In the
last decades, the prevalence of T2DM became higher than that of Type 1 Diabetes Mellitus …
last decades, the prevalence of T2DM became higher than that of Type 1 Diabetes Mellitus …
[HTML][HTML] Predictors of cardio-kidney complications and treatment failure in patients with chronic kidney disease and type 2 diabetes treated with SGLT2 inhibitors
C Kovesdy, N Schmedt, K Folkerts, K Bowrin, H Raad… - BMC medicine, 2022 - Springer
Background Clinical practice guidelines recommend sodium-glucose co-transporter 2
inhibitors (SGLT2is) to mitigate adverse kidney and cardiovascular outcomes in patients with …
inhibitors (SGLT2is) to mitigate adverse kidney and cardiovascular outcomes in patients with …
[HTML][HTML] Heat-related illness in emergency and critical care: recommendations for recognition and management with medico-legal considerations
G Savioli, C Zanza, Y Longhitano, A Nardone, A Varesi… - Biomedicines, 2022 - mdpi.com
Hyperthermia is an internal body temperature increase above 40.5° C; normally internal
body temperature is kept constant through natural homeostatic mechanisms. Heat-related …
body temperature is kept constant through natural homeostatic mechanisms. Heat-related …
[HTML][HTML] Role of zinc in diabetic kidney disease
G Gembillo, L Visconti, AE Giuffrida, V Labbozzetta… - Nutrients, 2022 - mdpi.com
Diabetic Kidney Disease (DKD) represents the most common cause of Chronic Kidney
Disease (CKD) in developed countries. Approximately 30% to 40% of diabetes mellitus (DM) …
Disease (CKD) in developed countries. Approximately 30% to 40% of diabetes mellitus (DM) …
[HTML][HTML] Acute Oncologic Complications: Clinical–Therapeutic Management in Critical Care and Emergency Departments
N Gri, Y Longhitano, C Zanza, V Monticone, D Fuschi… - Current …, 2023 - mdpi.com
Introduction. It is now known that cancer is a major public health problem; on the other hand,
it is less known, or rather, often underestimated, that a significant percentage of cancer …
it is less known, or rather, often underestimated, that a significant percentage of cancer …
[HTML][HTML] Translational approach to the protective effect of bilirubin in diabetic kidney disease
A Bianco, C Tiribelli, C Bellarosa - Biomedicines, 2022 - mdpi.com
Bilirubin has been regarded as a powerful endogenous antioxidant and anti-inflammatory
molecule, able to act on cellular pathways as a hormone. Diabetic kidney disease (DKD) is a …
molecule, able to act on cellular pathways as a hormone. Diabetic kidney disease (DKD) is a …
[HTML][HTML] Analysis of urine Raman spectra differences from patients with diabetes mellitus and renal pathologies
V Kavuru, RS Senger, JL Robertson, D Choudhury - PeerJ, 2023 - peerj.com
Background Chronic kidney disease (CKD) poses a major public health burden. Diabetes
mellitus (DM) is one of the major causes of CKD. In patients with DM, it can be difficult to …
mellitus (DM) is one of the major causes of CKD. In patients with DM, it can be difficult to …
[HTML][HTML] An analysis of DPV and DIVE registry patients with chronic kidney disease according to the finerenone phase III clinical trial selection criteria
P Bramlage, S Lanzinger, S Mühldorfer, K Milek… - Cardiovascular …, 2023 - Springer
Abstract Background The FIDELIO-DKD and FIGARO-DKD randomized clinical trials (RCTs)
showed finerenone, a novel non-steroidal mineralocorticoid receptor antagonist (MRA) …
showed finerenone, a novel non-steroidal mineralocorticoid receptor antagonist (MRA) …